NetworkNewsBreaks – Repros Therapeutics (NASDAQ: RPRX) Tumbles Pre-Market; Proellex Clinical Trial Remains on Partial Hold, per FDA
Shares of Repros Therapeutics (NASDAQ: RPRX) dropped 47% in pre-market trade after the reproductive disorders company said its clinical development program for Proellex, its oral delivery mechanism for telapristone acetate, will remain on partial clinical hold, per FDA review and feedback. Repros is now required to compile a large pre-approval safety database to support future development. The company says it is assessing increasing its focus on its uterine fibroid and endometriosis development program utilizing a vaginal drug delivery program for telapristone acetate, and that it expects to receive a European Patent related to the use of selective progesterone modulators (SPRM).…